Cargando…

Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models

Olverembatinib (HQP1351) is a third-generation BCR-ABL tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML) (including T315I-mutant disease), exhibits drug-drug interaction (DDI) potential through cytochrome P450 (CYP) enzymes CYP3A4, CYP2C9, CYP2C19, CYP1A2, and CYP2B6. A p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Zhiheng, Lei, Zihan, Yao, Xueting, Wang, Hengbang, Zhang, Miao, Hou, Zhe, Li, Yafen, Zhao, Yangyu, Li, Haiyan, Liu, Dongyang, Zhai, Yifan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792776/ https://www.ncbi.nlm.nih.gov/pubmed/36582520 http://dx.doi.org/10.3389/fphar.2022.1065130

Ejemplares similares

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2022)

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2022)

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
por: Jiang, Qian, et al.
Publicado: (2023)

FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia
por: Fang, Douglas D., et al.
Publicado: (2021)

Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors
por: Liu, Xuechao, et al.
Publicado: (2019)

Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients
por: Cui, Cheng, et al.
Publicado: (2021)

Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker
por: Zhang, Miao, et al.
Publicado: (2022)

Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients
por: Zhang, Miao, et al.
Publicado: (2021)

Dose decision of HSK7653 oral immediate release tablets in specific populations clinical trials based on mechanistic physiologically-based pharmacokinetic model
por: Zhang, Miao, et al.
Publicado: (2023)

Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects
por: Cui, Cheng, et al.
Publicado: (2021)

Physiologically-based pharmacokinetic modeling to predict drug-drug interactions of dabigatran etexilate and rivaroxaban in the Chinese older adults
por: Sia, Jie En Valerie, et al.
Publicado: (2023)

Development of a Virtual Chinese Pediatric Population Physiological Model Targeting Specific Metabolism and Kidney Elimination Pathways
por: Yao, Xueting, et al.
Publicado: (2021)

Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model
por: Cui, Cheng, et al.
Publicado: (2020)

A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia
por: Qian, Honglan, et al.
Publicado: (2022)

Case report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia
por: Ding, Jianghua, et al.
Publicado: (2023)

Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201
por: Zhang, Miao, et al.
Publicado: (2023)

Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model
por: Yang, Jianling, et al.
Publicado: (2020)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
por: Berton, Mattia, et al.
Publicado: (2022)

Current trends in drug metabolism and pharmacokinetics
por: Li, Yuhua, et al.
Publicado: (2019)

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
por: Rodriguez-Vera, Leyanis, et al.
Publicado: (2023)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Liu, Hongrui, et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naïve Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 1 trial
por: Liu, Dongyang, et al.
Publicado: (2021)

Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children
por: Zhou, W, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens
por: Cohen‐Rabbie, Sarit, et al.
Publicado: (2021)

Olverembatinib inhibits SARS‐CoV‐2‐Omicron variant‐mediated cytokine release in human peripheral blood mononuclear cells
por: Chan, Marina, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development
por: Wang, Kefei, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions
por: Chen, Yuan, et al.
Publicado: (2020)

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
por: Stader, Felix, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions
por: Hanke, Nina, et al.
Publicado: (2021)

Evaluation of drug–drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling
por: Ji, Tao, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development
por: Maharaj, A R, et al.
Publicado: (2014)

P394: FRONTLINE COMBINATION OF OLVEREMBATINIB AND PDT-ALL-2016 PEDIATRIC INSPIRED PROTOCOL IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Zhu, Kaibo, et al.
Publicado: (2023)

Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients
por: Yao, Xueting, et al.
Publicado: (2020)

Application of Physiologically‐Based Pharmacokinetic Modeling to Predict Gastric pH‐Dependent Drug–Drug Interactions for Weak Base Drugs
por: Dong, Zhongqi, et al.
Publicado: (2020)

Streamlining physiologically‐based pharmacokinetic model design for intravenous delivery of nanoparticle drugs
por: Le, Anh‐Dung, et al.
Publicado: (2022)

Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
por: Wu, Fan, et al.
Publicado: (2020)

Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
por: Min, Jee Sun, et al.
Publicado: (2016)

Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and Dasabuvir
por: Shebley, M, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t28m7921v4j74c0pmvupge9gm3